Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 14

1.

Dermal fibroblasts from patients with Parkinson's disease have normal GCase activity and autophagy compared to patients with PD and GBA mutations.

Collins LM, Drouin-Ouellet J, Kuan WL, Cox T, Barker RA.

Version 2. F1000Res. 2017 Sep 26 [revised 2018 Jan 1];6:1751. doi: 10.12688/f1000research.12090.2. eCollection 2017.

2.

α-Synuclein pre-formed fibrils impair tight junction protein expression without affecting cerebral endothelial cell function.

Kuan WL, Bennett N, He X, Skepper JN, Martynyuk N, Wijeyekoon R, Moghe PV, Williams-Gray CH, Barker RA.

Exp Neurol. 2016 Nov;285(Pt A):72-81. doi: 10.1016/j.expneurol.2016.09.003. Epub 2016 Sep 12.

PMID:
27632900
3.

Progressive tauopathy in P301S tau transgenic mice is associated with a functional deficit of the olfactory system.

Yang S, Kuan WL, Spillantini MG.

Eur J Neurosci. 2016 Sep;44(6):2396-403. doi: 10.1111/ejn.13333. Epub 2016 Sep 5.

PMID:
27422327
4.

Characterization and Visualization of Vesicles in the Endo-Lysosomal Pathway with Surface-Enhanced Raman Spectroscopy and Chemometrics.

Huefner A, Kuan WL, Müller KH, Skepper JN, Barker RA, Mahajan S.

ACS Nano. 2016 Jan 26;10(1):307-16. doi: 10.1021/acsnano.5b04456. Epub 2015 Dec 18.

PMID:
26649752
5.

The human cytomegalovirus non-coding Beta2.7 RNA as a novel therapeutic for Parkinson's disease--Translational research with no translation.

Poole E, Kuan WL, Barker R, Sinclair J.

Virus Res. 2016 Jan 2;212:64-9. doi: 10.1016/j.virusres.2015.05.007. Epub 2015 May 21. Review.

PMID:
26003955
6.

Cerebrovascular and blood-brain barrier impairments in Huntington's disease: Potential implications for its pathophysiology.

Drouin-Ouellet J, Sawiak SJ, Cisbani G, Lagacé M, Kuan WL, Saint-Pierre M, Dury RJ, Alata W, St-Amour I, Mason SL, Calon F, Lacroix S, Gowland PA, Francis ST, Barker RA, Cicchetti F.

Ann Neurol. 2015 Aug;78(2):160-77. doi: 10.1002/ana.24406. Epub 2015 Apr 9.

PMID:
25866151
7.

Gold nanoparticles explore cells: cellular uptake and their use as intracellular probes.

Huefner A, Septiadi D, Wilts BD, Patel II, Kuan WL, Fragniere A, Barker RA, Mahajan S.

Methods. 2014 Jul 1;68(2):354-63. doi: 10.1016/j.ymeth.2014.02.006. Epub 2014 Feb 28.

PMID:
24583117
8.

Intracellular SERS nanoprobes for distinction of different neuronal cell types.

Huefner A, Kuan WL, Barker RA, Mahajan S.

Nano Lett. 2013 Jun 12;13(6):2463-70. doi: 10.1021/nl400448n. Epub 2013 May 10.

9.

A novel neuroprotective therapy for Parkinson's disease using a viral noncoding RNA that protects mitochondrial complex I activity.

Kuan WL, Poole E, Fletcher M, Karniely S, Tyers P, Wills M, Barker RA, Sinclair JH.

J Exp Med. 2012 Jan 16;209(1):1-10. doi: 10.1084/jem.20111126. Epub 2011 Dec 19.

10.

Graft-induced dyskinesias in Parkinson's disease: what is it all about?

Barker RA, Kuan WL.

Cell Stem Cell. 2010 Aug 6;7(2):148-9. doi: 10.1016/j.stem.2010.07.003.

12.

The future of cell therapies in the treatment of Parkinson's disease.

Laguna Goya R, Kuan WL, Barker RA.

Expert Opin Biol Ther. 2007 Oct;7(10):1487-98. Review.

PMID:
17916042
13.
14.

Increased capacity for axonal outgrowth using xenogenic tissue in vitro and in a rodent model of Parkinson's disease.

Kuan WL, Hurelbrink CB, Barker RA.

Xenotransplantation. 2006 May;13(3):233-47.

PMID:
16756566

Supplemental Content

Loading ...
Support Center